New Ideas Emerge Concerning How to Treat Long COVID

Three papers and a private grant have caught this writer&rsquo;s attention as defining the Long COVID landscape as we enter autumn 2022: a paper from Harvard, a paper from Yale, an update from a Cedars-Sinai and University of Pittsburgh team that has conjectured since 2020 that S1 acts as a superantigen&nbsp;and the awarding of funds to the PolyBio Research Foundation, part of the Long Covid Research Initiative, for what they call the Intestinal Tissue SARS-CoV-2 Persistence Project.
Consensus has emerged on three points: